Stock listing

NASDAQ:TNGX Tango Therapeutics, Inc. Stock

Home listing (NASDAQ) of Tango Therapeutics, Inc.

Follow Tango Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TNGX

$21.73 USD -0.16 (-0.7%)

Close on Nov 20, 2026

Past year +144.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$21.63 – $23.05 USDNov 20, 2026
Volume
1.74M sharesNov 20, 2026
Market cap
$3.68B USDAt the close on Nov 20, 2026 · price × 169.5M shares outstanding
52-week range
$8.30 – $34.39 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$80.18M USDMedian day 2.87M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tango Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TNGX · Home$21.73 USD-0.16 (-0.7%)1,740,329$22.11$23.05$21.63$21.89Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TNGX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$21.73-0.16-0.7%$22.11$23.05$21.631,740,329
$21.89-0.22-1.0%$22.03$22.36$21.272,746,141
$22.11-2.06-8.5%$24.08$24.32$22.052,057,514
$24.17-1.33-5.2%$24.85$25.87$24.151,580,684
$25.50+0.65+2.6%$24.76$25.58$23.662,706,075
$24.85-0.88-3.4%$25.33$25.37$23.613,488,265
$25.73+1.43+5.9%$24.68$26.41$23.873,866,649
$24.30+1.56+6.9%$22.74$24.65$22.384,560,772
$22.74+1.24+5.8%$21.63$23.28$21.122,516,737
$21.50+0.63+3.0%$20.74$22.11$20.742,129,301
$20.87-2.31-10.0%$23.25$23.58$20.783,403,948
$23.18+0.010.0%$24.16$24.75$22.672,464,255
$23.17+1.41+6.5%$22.09$23.97$21.992,458,054
$21.76-0.96-4.2%$22.65$23.31$21.723,681,587
$22.72+0.19+0.8%$22.11$22.75$21.715,279,230
$22.53+0.30+1.3%$22.36$23.58$22.363,369,953
$22.23-0.66-2.9%$22.86$23.71$22.143,309,657
$22.89+0.695+3.1%$22.02$23.50$21.813,322,765
$22.20-1.145-4.9%$23.41$23.95$22.005,370,456
$23.34-4.59-16.4%$25.54$25.94$22.6815,852,900
$27.93+0.95+3.5%$26.67$27.98$25.945,964,100
$26.98+1.73+6.9%$25.55$27.60$25.355,557,300
$25.25+1.72+7.3%$23.95$25.35$23.202,673,700
$23.53+1.49+6.8%$22.49$23.86$22.361,870,800
$22.04-0.66-2.9%$23.12$23.17$21.823,688,300
$22.70+0.51+2.3%$22.27$22.96$21.792,903,900
$22.19-0.03-0.1%$21.98$23.02$21.523,438,800
$22.22-1.95-8.1%$23.85$24.11$21.859,619,100
$24.17+0.36+1.5%$23.57$24.47$23.342,868,000
$23.81+1.24+5.5%$22.60$24.12$22.443,098,800
$22.57+0.74+3.4%$21.57$22.68$20.985,074,400
$21.83-0.07-0.3%$21.64$22.46$21.383,392,800
$21.90-1.18-5.1%$23.16$23.16$21.364,351,000
$23.08-0.16-0.7%$23.29$23.56$22.251,943,900
$23.24-1.21-4.9%$25.09$25.09$23.095,253,600
$24.45-0.50-2.0%$24.90$25.43$23.952,910,300
$24.95+0.53+2.2%$24.64$25.41$23.823,660,500
$24.42+0.12+0.5%$24.32$24.80$23.182,992,200
$24.30-0.62-2.5%$24.92$24.92$23.702,413,400
$24.92+0.29+1.2%$24.95$25.38$24.083,255,000
$24.63+0.18+0.7%$23.99$24.83$23.502,290,600
$24.45-1.08-4.2%$25.40$25.92$24.064,957,100
$25.53+3.20+14.3%$22.33$25.75$22.256,968,700
$22.33+0.58+2.7%$21.90$22.74$21.632,555,300
$21.75-1.74-7.4%$23.33$23.55$21.726,242,500
$23.49+0.14+0.6%$23.79$24.63$23.411,721,900
$23.35-0.54-2.3%$24.17$24.39$23.002,835,500
$23.89-0.65-2.6%$24.55$24.55$23.591,791,000
$24.54+0.76+3.2%$23.98$24.99$23.442,010,900
$23.78+0.41+1.8%$23.72$24.63$23.192,279,300
$23.37-0.63-2.6%$23.16$24.30$23.163,437,300
$24.00+1.30+5.7%$22.99$25.52$22.634,664,500
$22.70+0.18+0.8%$22.50$23.08$22.262,424,800
$22.52-0.24-1.1%$22.48$22.94$22.291,457,400
$22.76+0.44+2.0%$22.50$22.79$22.131,343,700
$22.32-0.03-0.1%$22.62$23.12$21.641,916,400
$22.35-0.49-2.1%$22.60$23.06$22.071,544,300
$22.84-0.50-2.1%$23.28$23.50$22.611,850,100
$23.34-1.94-7.7%$24.93$25.09$23.281,999,000
$25.28-0.19-0.7%$25.39$26.85$25.242,037,400
$25.47+0.70+2.8%$24.65$27.00$24.263,173,900
$24.77+0.26+1.1%$25.04$25.61$24.352,283,248
$24.51+0.63+2.6%$23.60$24.68$22.912,088,761
$23.88+0.37+1.6%$23.95$24.36$23.482,488,700
$23.51-1.69-6.7%$25.51$25.67$23.152,064,600
Ticker
NASDAQ:TNGX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Tango Therapeutics, Inc. news

Tango Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 92 in all · newest Nov 9, 2026 · oldest 2021
Decks
16 decks · latest Oct 23, 2026

Where Tango Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TNGX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TNGXBOATSUnited StatesUSD

Valuation

Price/book 3.8× against a median of 4.0×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.74B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.41

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tango Therapeutics, Inc. · NASDAQ:TNGXUS$3.68BUS$2.74Bn/an/an/a3.8×n/a0.0×1.41
Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192US$3.90BUS$3.18B7.5×4.3×n/a5.2×69.3%0.1×n/a
Definium Therapeutics, Inc. · NASDAQ:DFTXUS$3.88BUS$2.87Bn/an/an/a4.0×n/a0.0×1.14
CRISPR Therapeutics AG · NASDAQ:CRSPUS$3.79BUS$2.11Bn/a83.7×n/a2.3×n/a0.4×1.64
Xenon Pharmaceuticals Inc. · NASDAQ:XENEUS$3.64BUS$2.70Bn/an/an/a3.2×n/a0.0×0.80
Relay Therapeutics, Inc. · NASDAQ:RLAYUS$3.56BUS$2.74Bn/a265×n/a4.3×n/a0.0×1.48
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336US$3.56BUS$3.42B7.6×5.1×n/a2.7×69.9%0.0×n/a
Enliven Therapeutics, Inc. · NASDAQ:ELVNUS$3.42BUS$2.54Bn/an/an/a3.9×n/a0.0×0.89
Disc Medicine, Inc. · NASDAQ:IRONUS$3.42BUS$2.80Bn/an/an/a5.7×n/a0.1×0.94
Viridian Therapeutics, Inc. · NASDAQ:VRDNUS$3.40BUS$2.69Bn/a102×n/a5.9×n/a0.4×1.00
Parabilis Medicines, Inc. · NASDAQ:PBLSUS$3.39BUS$2.53Bn/an/an/a3.4×n/a0.0×n/a
Median of the othersUS$3.56BUS$2.72B7.6×83.7×4.0×69.6%0.0×1.00

Forecasts

11 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
47.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.45 · 13 analysts

Team and board

Officers

OfficerRole
Malte PetersPresident & Chief Executive Officer, Tango Therapeutics
Robert AzelbyChairman; Former President and CEO, Eliem Therapeutics, Inc.
Matthew GallChief Financial Officer
Sung LeeExecutive Vice President and Chief Financial Officer, Cytokinetics
Adam CrystalPresident, Research & Development
Mace RothenbergPresident and Executive Director, Museum of Medicine and Biomedical Discovery
Julie FogartySVP, General Counsel
Janice KaptySVP, Corporate Strategy and Project Leadership
Lesley Ann CalhounEVP, Aligos Therapeutics
Fatma OcakChief Commercialization Officer
Julie CarreteroChief Human Resources Officer
Philippe SerranoChief Regulatory Officer
Yen-Ching ChuaChief Development Operations Officer

Board

DirectorRole
Robert AzelbyChairman; Former President and CEO, Eliem Therapeutics, Inc.
Mace RothenbergPresident and Executive Director, Museum of Medicine and Biomedical Discovery
Malte PetersPresident & Chief Executive Officer, Tango Therapeutics
Sung LeeExecutive Vice President and Chief Financial Officer, Cytokinetics

Events

Next results
Mar 4, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+5.8%
Q2 2026Aug 11, 2026 · Before open−4.8%
Q1 2026May 13, 2026+5.8%
Q4 2025Mar 5, 2026 · Before open+36.3%
Q3 2025Nov 4, 2025 · Before open0.0%
Q2 2025Aug 5, 2025 · Before open+4.9%
Q1 2025May 12, 2025 · Before open+14.9%
Q4 2024Mar 17, 2025 · Before open0.0%
Q3 2024Nov 6, 2024 · Before open−37.5%
Q2 2024Aug 7, 2024 · Before open−3.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open+0.8%
Q4 2023Mar 18, 2024 · Before open−7.1%
Q3 2023Nov 8, 2023 · Before open+3.8%
Q2 2023Aug 7, 2023 · Before open+1.2%
Q1 2023May 9, 2023 · Before open+6.4%
Q4 2022Mar 27, 2023 · Before open−9.3%
Q3 2022Nov 10, 2022 · Before open−5.3%
Q2 2022Aug 10, 2022 · Before open+22.4%
Q1 2022May 11, 2022 · Before open−7.6%
Q4 2021Mar 28, 2022 · Before open+0.3%

Open Events

Decks

DeckKindSlidesDate
PDAC Investor Presentation (October 2026)Conference35 slidesOct 23, 2026
PDAC Investor Presentation (October 2026)Conference35 slidesOct 23, 2026
Investor Presentation (August 2026)Investor deck36 slidesAugust 2026
Technical Presentation (June 2026)Technical31 slidesJun 8, 2026
JP Morgan Healthcare Conference 2026Conference24 slidesJan 8, 2026
AACR 2026Conference22 slides2026
Technical Presentation (November 2025)Technical18 slidesNov 4, 2025
Technical Presentation (October 2025)Technical26 slidesOct 30, 2025
Corporate Update (October 2025)Corporate update20 slidesOct 23, 2025
Botton Champalimaud International Pancreatic Cancer Conference 2025Conference16 slidesOctober 2025
All 16 decks
DeckKindSlidesDate
Investor Presentation (May 2025)Investor deck34 slidesMay 2025
Investor Presentation (January 2025)Investor deck40 slidesJan 13, 2025
SPAC Merger (April 2021)SPAC merger14 slidesApr 14, 2021
SPAC Merger (April 2021)SPAC merger14 slidesApril 2021
Technical Presentation (2021)Technical9 slides2021
Technical Presentation (2021)Technical7 slides2021

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$600M · US$30 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Cantor (co-lead), Stifel (co-lead)
Jun 10, 2026
Public offering of common stock and pre-funded warrants
Announced: about US$210M · US$8.66 a share · Leerink Partners +1
Dealers: Leerink Partners (co-lead), Cantor (co-lead)
Buyers: Farallon Capital Management; TCGX; Balyasny Asset Management; Woodline Partners LP; Invus; Adage Capital Management LP; Boxer Capital Management; Logos Capital; Nantahala Capital; accounts advised by T. Rowe Price Investment Management, Inc.
Oct 23, 2025
Private placement of common stock
Announced: about US$15M · US$8.66 a share
Buyers: Nextech (led the PIPE)
Oct 23, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as BCTG Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a share on Sep 2, 2020.

Price
US$10.00 a share
Shares offered
14,500,000 shares of common stock
Offering size
US$145 million
Underwriters' option
Up to 2,175,000 more shares
Listing
BCTG on the Nasdaq Capital Market
Underwriter
SVB Leerink
Shares delivered
On or about Sep 8, 2020

Steps

StepWhen
Filed publiclyJul 30, 2020
Amended onceAug 31, 2020
Shares registered with an exchangeSep 2, 2020
Declared effective by the SECSep 2, 2020
Final prospectus, with the priceSep 4, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Sep 4, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue62.4M42.1M36.5M24.9M37.0M7.66M24.6M
Cost of revenue2.28M2.50M115.2M4.03M1.97M1.63M32.3M
Gross profit60.1M42.1M36.5M24.9M37.0M6.03M-7.63M
Research and development132.2M143.9M115.2M105.9M77.6M50.0M32.3M
Selling, general and administrative41.5M43.7M35.5M30.0M17.6M9.87M7.54M
Operating income-111.3M-145.6M-114.2M-111.1M-58.2M-52.2M-15.2M
Depreciation and amortization2.28M2.50M2.42M1.61M897.0K718.0K643.0K
EBITDA-109.0M-143.1M-111.8M-109.5M-57.3M-51.5M-14.5M
Interest expense2.95M1.14M00
Income before tax-101.6M-130.1M-101.6M-108.1M-57.9M-52.0M-14.1M
Income tax4.00K208.0K134.0K54.0K292.0K0
Net income-101.6M-130.3M-101.7M-108.2M-58.2M-52.0M-14.1M
Earnings per share, basic-0.87-1.19-1.08-1.23-0.94-1.63-0.16
Earnings per share, diluted-0.87-1.19-1.08-1.23-0.94-1.63

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents112.3M69.5M66.4M60.0M142.7M28.4M22.9M
Short-term investments230.9M188.4M270.5M306.2M342.5M161.9M17.5M
Receivables02.00M2.00M2.00M
Inventory567.0K567.0K
Current assets353.8M266.3M346.5M375.3M492.3M193.6M41.7M
Property, plant and equipment6.87M8.10M9.91M10.9M4.83M3.82M11.8M
Total assets398.7M316.5M402.6M436.5M500.2M207.3M55.8M
Accounts payable1.18M1.60M2.79M4.45M3.23M1.84M670.0K
Current liabilities21.7M38.2M45.9M55.5M40.7M40.9M25.9M
Total debt33.6M36.5M38.9M41.1M1.50M7.88M8.54M
Total liabilities52.5M117.0M149.5M187.0M155.4M168.7M47.9M
Shareholders' equity346.2M199.5M253.1M249.5M344.7M38.6M7.91M
Shares outstanding135.9M107.7M102.2M88.2M87.6M40.4M87.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-138.9M-131.5M-118.0M-109.1M-59.5M70.1M-24.8M
Capital spending-1.05M-754.0K-1.53M-7.69M-1.84M-1.11M-1.82M
Free cash flow-139.9M-132.3M-119.5M-116.8M-61.4M69.0M-26.6M
Cash from investing-40.9M86.1M41.4M26.4M-183.4M-145.5M848.0K
Cash from financing222.5M47.7M82.4M1.61M357.3M80.9M11.0M
Share buybacks31.0M
Change in cash42.7M2.29M5.85M-81.1M114.4M5.49M25.2M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
8-K · Current reportNov 9, 2026ResultsSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
8-K · Current reportOct 23, 2026Current reportSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
144 · Notice of proposed saleSep 22, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
8-K · Current reportAug 11, 2026Current reportSEC
424B5 · ProspectusAug 11, 2026Offer documentSEC
8-K · Current reportAug 11, 2026ResultsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K/A · Current report, amendedAug 7, 2026Management or board changeSEC
8-K · Current reportAug 6, 2026Management or board changeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Management or board changeSEC
144 · Notice of proposed saleJun 17, 2026Other filingsSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
8-K · Current reportJun 10, 2026Material contractSEC
424B5 · ProspectusJun 10, 2026Offer documentSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
FWP · Free writing prospectusJun 9, 2026Offer documentSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
424B5 · ProspectusJun 8, 2026Offer documentSEC
8-K · Current reportJun 8, 2026Current reportSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 13, 2026ResultsSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 11, 2026Big-stake noticeSEC
8-K · Current reportMay 8, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 4, 2026Big-stake noticeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
3 · Initial statement of ownershipApr 24, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 24, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportApr 15, 2026Management or board changeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
144 · Notice of proposed saleMar 25, 2026Other filingsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
8-K · Current reportMar 5, 2026ResultsSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026ResultsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveDec 11, 2025Other filingsSEC
CORRESP · Letter to the SECDec 8, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 21, 2025Big-stake noticeSEC
8-K · Current reportNov 21, 2025Material contractSEC
S-3ASR · Registration statementNov 21, 2025Offer documentSEC
S-3 · Registration statementNov 21, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
8-K · Current reportNov 4, 2025ResultsSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
DOct 28, 2025Other filingsSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
8-K · Current reportOct 24, 2025Material contractSEC
424B5 · ProspectusOct 24, 2025Offer documentSEC
144 · Notice of proposed saleOct 23, 2025Other filingsSEC
FWP · Free writing prospectusOct 23, 2025Offer documentSEC
8-K · Current reportOct 23, 2025ResultsSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
144 · Notice of proposed saleSep 25, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeSep 22, 2025Big-stake noticeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
144 · Notice of proposed saleSep 17, 2025Other filingsSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
144 · Notice of proposed saleSep 8, 2025Other filingsSEC
144 · Notice of proposed saleSep 5, 2025Other filingsSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
8-K · Current reportAug 25, 2025Management or board changeSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
144 · Notice of proposed saleAug 19, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 13, 2025Big-stake noticeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 22, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 20, 2025Other filingsSEC
CORRESP · Letter to the SECMay 19, 2025Other filingsSEC
S-3 · Registration statementMay 12, 2025Offer documentSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
DEFR14AApr 23, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 11, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 2, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 20, 2024Big-stake noticeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 8, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
144 · Notice of proposed saleNov 6, 2024Other filingsSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedOct 28, 2024Big-stake noticeSEC
4 · Change in ownershipOct 28, 2024Insider tradeSEC
144 · Notice of proposed saleOct 25, 2024Other filingsSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
144 · Notice of proposed saleOct 22, 2024Other filingsSEC
3 · Initial statement of ownershipOct 22, 2024Insider tradeSEC
144 · Notice of proposed saleOct 22, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedOct 15, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 15, 2024Big-stake noticeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
144 · Notice of proposed saleSep 13, 2024Other filingsSEC
4 · Change in ownershipSep 9, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
144 · Notice of proposed saleSep 5, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedSep 4, 2024Big-stake noticeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
144 · Notice of proposed saleAug 30, 2024Other filingsSEC
4 · Change in ownershipAug 29, 2024Insider tradeSEC
144 · Notice of proposed saleAug 27, 2024Other filingsSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
144 · Notice of proposed saleAug 19, 2024Other filingsSEC
144 · Notice of proposed saleAug 16, 2024Other filingsSEC

This page holds 200 of 432 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tango Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
169,455,160
Fully diluted
169,455,160

Fully diluted

LineSharesAs of
Common shares169,455,160Nov 2, 2026

Share count over time

CountShares
Nov 2, 2026169,455,160

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Rtw Investments, LP14MUS$351MSep 30, 2026
Fidelity13.1MUS$328MSep 30, 2026
BlackRock13.1MUS$328MSep 30, 2026
Goldman Sachs11.4MUS$285MSep 30, 2026
Boxer Capital Management, LLC10.5MUS$263MSep 30, 2026
Vanguard9.36MUS$233MSep 30, 2026
State Street7.32MUS$183MSep 30, 2026
Adage Capital Partners Gp, L.L.C.7.26MUS$181MSep 30, 2026
Paradigm Biocapital Advisors LP6.96MUS$174MSep 30, 2026
Siren, L.L.C.6.78MUS$169MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
TCG Crossover Management, LLC6.77MUS$169MSep 30, 2026
T. Rowe Price6.36MUS$159MSep 30, 2026
Deerfield Management Company, L.P.5.18MUS$129MSep 30, 2026
Janus Henderson4.94MUS$123MSep 30, 2026
Farallon Capital Management, L.L.C.4.55MUS$114MSep 30, 2026
Deep Track Capital, LP4.5MUS$112MSep 30, 2026
Geode Capital4.04MUS$101MSep 30, 2026
Woodline Partners LP4MUS$99.8MSep 30, 2026
Holocene Advisors, LP3.46MUS$86.4MSep 30, 2026
Polar Capital Holdings Plc3.46MUS$86.4MSep 30, 2026
Orbimed Advisors LLC2.78MUS$69.3MSep 30, 2026
Perceptive Advisors LLC2.69MUS$67.2MSep 30, 2026
Caligan Partners LP2.5MUS$62.4MSep 30, 2026
Franklin Templeton2.36MUS$54.7MSep 30, 2026
Seven Fleet Capital Management LP2.23MUS$55.7MSep 30, 2026
Logos Global Management LP2.15MUS$53.6MSep 30, 2026
Trv Gp IV, LLC1.94MUS$48.5MSep 30, 2026
Balyasny Asset Management L.P.1.91MUS$47.7MSep 30, 2026
GordonMD Global Investments LP1.85MUS$9.02MSep 30, 2026
JPMorgan1.75MUS$42.8MSep 30, 2026
Federated Hermes, Inc.1.4MUS$35MSep 30, 2026
Vivo Capital, LLC1.38MUS$34.4MSep 30, 2026
Bank of America1.34MUS$33.5MSep 30, 2026
Northern Trust1.33MUS$33.1MSep 30, 2026
Schwab1.32MUS$32.9MSep 30, 2026
Dv Equities, LLC1.29MUS$32.2MSep 30, 2026
American Century1.28MUS$32MSep 30, 2026
Lord, Abbett & Co. LLC1.17MUS$29.2MSep 30, 2026
Voya Investment Management LLC1.11MUS$27.6MSep 30, 2026
Trails Edge Capital Partners, LP1.1MUS$27.4MSep 30, 2026
Bellevue Group AG1.1MUS$27.4MSep 30, 2026
Fisher Asset Management, LLC1.07MUS$26.7MSep 30, 2026
Integral Health Asset Management, LLC1MUS$22.5MSep 30, 2026
Stempoint Capital LP989KUS$24.7MSep 30, 2026
ArrowMark Colorado Holdings LLC840KUS$21MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.838KUS$20.9MSep 30, 2026
Nuveen814KUS$20.3MSep 30, 2026
Soleus Capital Management, L.P.802KUS$20MSep 30, 2026
UBS778KUS$19.4MSep 30, 2026
First Turn Management, LLC767KUS$19.1MSep 30, 2026

This page holds 50 of 248 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund4.4MUS$137MJun 30, 2026
iShares Russell 2000 ETF3.61MUS$113MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.89MUS$90.4MJun 30, 2026
Fidelity Growth Company Fund2.47MUS$54.3MMay 31, 2026
Select Biotechnology Portfolio2.34MUS$51.4MMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.1.55MUS$48.3MJun 30, 2026
Fidelity Small Cap Index Fund1.54MUS$41.9MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1.4MUS$43.8MJun 30, 2026
Vanguard Extended Market Index Fund1.37MUS$42.7MJun 30, 2026
iShares Russell 2000 Growth ETF1.22MUS$38.3MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.2MUS$37.5MJun 30, 2026
Federated Hermes Kaufmann Fund873KUS$23.7MJul 31, 2026
Lord Abbett Developing Growth Fund Inc851KUS$23.1MJul 31, 2026
Small Cap Growth Fund773KUS$21MJul 31, 2026
iShares Biotechnology ETF751KUS$23.5MJun 30, 2026
Fidelity Series Growth Company Fund672KUS$14.8MMay 31, 2026
Fidelity Growth Company K6 Fund619KUS$13.6MMay 31, 2026
Janus Henderson Global Life Sciences Fund586KUS$18.3MJun 30, 2026
Vanguard Russell 2000 Index Fund570KUS$12.5MMay 31, 2026
Franklin Biotechnology Discovery Fund522KUS$14.2MJul 31, 2026
Federated Hermes Kaufmann Small Cap Fund513KUS$14MJul 31, 2026
Fidelity Extended Market Index Fund508KUS$11.2MMay 31, 2026
Franklin Small Cap Growth Fund507KUS$13.8MJul 31, 2026
Vanguard Explorer Fund505KUS$13.7MJul 31, 2026
JPMorgan Small Cap Growth Fund498KUS$15.6MJun 30, 2026
Schwab U.S. Small-Cap ETF471KUS$10.4MMay 31, 2026
Fidelity Small Cap Growth Fund464KUS$12.6MJul 31, 2026
Eventide Healthcare & Life Sciences Fund400KUS$12.5MJun 30, 2026
Fidelity Contrafund383KUS$12MJun 30, 2026
Schwab Small-Cap Index Fund341KUS$9.28MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account336KUS$10.5MJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund300KUS$8.16MJul 31, 2026
Master Small Cap Index Series258KUS$8.07MJun 30, 2026
Invesco Dorsey Wright SmallCap Momentum ETF249KUS$5.48MMay 31, 2026
JNL Multi-Manager Small Cap Value Fund246KUS$7.69MJun 30, 2026
Fidelity Small Cap Growth K6 Fund241KUS$6.54MJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund225KUS$6.1MJul 31, 2026
Fidelity Total Market Index Fund187KUS$4.11MMay 31, 2026
Invesco Dorsey Wright Healthcare Momentum ETF187KUS$5.07MJul 31, 2026
Nuveen Small Cap Blend Index Fund182KUS$4.95MJul 31, 2026
U.S. Small Cap Portfolio171KUS$4.65MJul 31, 2026
Fidelity Series Small Cap Core Fund164KUS$4.45MJul 31, 2026
JPMorgan Small Cap Blend Fund158KUS$4.95MJun 30, 2026
U.S. Micro Cap Portfolio154KUS$4.18MJul 31, 2026
T. Rowe Price Small-Mid Cap ETF153KUS$4.8MJun 30, 2026
EQ/2000 Managed Volatility Portfolio151KUS$4.71MJun 30, 2026
Fidelity Series Total Market Index Fund149KUS$3.28MMay 31, 2026
Vanguard U.S. Momentum Factor ETF147KUS$3.22MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF142KUS$4.45MJun 30, 2026
Nuveen Quant Small/Mid Cap Equity Fund142KUS$3.85MJul 31, 2026

This page holds 50 of 232 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ketchum John B
Director
Sale3,333USD 24.08US$80,259Nov 17, 2026
Crystal Adam
Officer: President, R&D
Sale5,000USD 25.00US$125KNov 11, 2026
Newcomb Jessica
Officer: Principal Accounting Officer
Sale5,571USD 22.28US$124KNov 2, 2026
Newcomb Jessica
Officer: Principal Accounting Officer
Sale1,460USD 22.98US$33,553Nov 2, 2026
Crystal Adam
Officer: President, R&D
Sale3,900USD 22.26US$86,821Nov 2, 2026
Crystal Adam
Officer: President, R&D
Sale1,100USD 22.99US$25,287Nov 2, 2026
Crystal Adam
Officer: President, R&D
Sale26,400USD 24.45US$646KOct 1, 2026
Crystal Adam
Officer: President, R&D
Sale600USD 25.32US$15,192Oct 1, 2026
Newcomb Jessica
Officer: Principal Accounting Officer
Sale700USD 22.80US$15,960Sep 22, 2026
Newcomb Jessica
Officer: Principal Accounting Officer
Sale5,100USD 23.97US$122KSep 22, 2026
All 22 trades
TradeTradeSharesPriceValueDate
Newcomb Jessica
Officer: Principal Accounting Officer
Sale2,400USD 25.17US$60,408Sep 22, 2026
Crystal Adam
Officer: President, R&D
Sale27,000USD 22.37US$604KSep 1, 2026
Crystal Adam
Officer: President, R&D
Sale5,267USD 26.79US$141KAug 3, 2026
Crystal Adam
Officer: President, R&D
Sale21,733USD 27.35US$594KAug 3, 2026
Crystal Adam
Officer: President, R&D
Sale19,629USD 29.34US$576KJul 1, 2026
Crystal Adam
Officer: President, R&D
Sale7,371USD 30.25US$223KJul 1, 2026
Crystal Adam
Officer: President, R&D
Sale6,140USD 22.25US$137KJun 1, 2026
Crystal Adam
Officer: President, R&D
Sale20,860USD 23.06US$481KJun 1, 2026
Crystal Adam
Officer: President, R&D
Sale25,900USD 21.19US$549KMay 1, 2026
Crystal Adam
Officer: President, R&D
Sale1,100USD 22.00US$24,200May 1, 2026
Crystal Adam
Officer: President, R&D
Sale38,460USD 25.00US$962KApr 15, 2026
Crystal Adam
Officer: President, R&D
Sale27,000USD 21.20US$572KApr 1, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC15.00%25.3MOct 30, 2026Schedule 13G
Davis Aaron I.10.00%10.7MDec 30, 2024Schedule 13D
Rtw Investments, LP9.30%13.3MMar 31, 2026Schedule 13G
BlackRock, Inc.6.30%8.48MDec 31, 2025Schedule 13G
Goldman Sachs Group Inc6.00%9.74MJun 30, 2026Schedule 13G
Third Rock Ventures IV, L.P.4.74%6.37MFeb 6, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Azelby
Other companies: Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Cardinal Health, Inc. (Director · Since at least Mar 1, 2024); ADC Therapeutics SA (Director · Since at least Jan 2, 2024); Aduro Biotech Inc (Director · Apr 10, 2023 – Aug 11, 2023 · Past); Climb Bio, Inc. (President & CEO, Director · Aug 9, 2021 – Oct 31, 2022 · Past); Immunomedics Inc (Director · Feb 26, 2020 – Oct 23, 2020 · Past); Clovis Oncology Inc (Director · Oct 11, 2018 – Jun 10, 2021 · Past); Alder BioPharmaceuticals Inc (President and CEO, Director · Jun 13, 2018 – Oct 22, 2019 · Past); Cascadian Therapeutics Inc (Director · Mar 31, 2017 – Mar 9, 2018 · Past); Juno Therapeutics Inc (EVP & Chief Commercial Officer · Nov 1, 2015 – Mar 5, 2018 · Past)
Chairman; Former President and CEO, Eliem Therapeutics, Inc. · Since at least Jun 19, 2026
Richard Heyman
Other companies: Enliven Therapeutics, Inc. (Director · Since at least Feb 23, 2023); PMV Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2020); ORIC Pharmaceuticals, Inc. (Chairman · Since at least Apr 23, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Gritstone bio, Inc. (Director · Sep 27, 2018 – Jun 17, 2022 · Past)
Director · Sep 2, 2020 – Sep 2, 2020 · Past
Daniella Beckman
Other companies: Upstream Bio, Inc. (Member, Board of Directors · Since at least Oct 10, 2024); Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past)
Chief Financial Officer · Since at least Aug 10, 2021
Alexis Borisy
Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Blueprint Medicines Corp (Director · Since at least Jun 18, 2025); Relay Therapeutics, Inc. (Director · Since at least Jun 6, 2025)
Director · Since at least Jun 5, 2025
Charles Baum
Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Jun 22, 2023); PMV Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2021); Poseida Therapeutics Inc (Director · May 16, 2022 – Jan 8, 2025 · Past); Immunomedics Inc (Director · Feb 23, 2019 – Oct 23, 2020 · Past)
Director · Sep 2, 2020 – Sep 2, 2020 · Past
Barbara Weber
Other companies: Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); OPY Acquisition I Corp (Director · Oct 26, 2021 – Oct 26, 2021 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Oct 8, 2024 · Past)
Director, Executive Chair, Director · Since at least Aug 10, 2021
Sung Lee
Other companies: Cytokinetics, Incorporated (EVP, Chief Financial Officer · Since at least Apr 26, 2024); Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Mar 27, 2023 – Mar 27, 2024 · Past); Sangamo Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 31, 2019 – Nov 25, 2020 · Past)
Executive Vice President and Chief Financial Officer, Cytokinetics · Since at least Jan 2, 2026
Aaron I Davis
Other companies: Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jun 11, 2024 · Past)
Director · Jun 8, 2022 – Aug 11, 2023 · Past
Matthew Gall
Other companies: Kalaris Therapeutics, Inc. (Chief Financial Officer · Since at least Nov 3, 2025); Iteos Therapeutics Inc (Chief Financial Officer · Since at least Jul 23, 2020)
Chief Financial Officer · Since at least Apr 15, 2026
Adam Crystal
Other companies: C4 Therapeutics, Inc. (Chief Medical Officer · May 25, 2022 – Jan 30, 2023 · Past)
President, Research & Development · Since at least Feb 27, 2023
All 27 people
PersonSeat
Joseph Lewis
Other companies: Inseego Corp. (Director · Aug 9, 2019 – Aug 9, 2019 · Past)
Director · Aug 11, 2023 – Aug 11, 2023 · Past
Mace Rothenberg
Other companies: Surrozen, Inc. (Director · Since at least Aug 11, 2021)
Director · Since at least Aug 10, 2021
Aaron WeitzmanChief Medical Officer · Dec 1, 2022 – Dec 1, 2022 · Past
Alan HuangChief Scientific Officer · Aug 10, 2021 – Mar 1, 2023 · Past
Douglas BarryGeneral Counsel · Mar 1, 2023 – Feb 4, 2025 · Past
Fatma OcakChief Commercialization Officer · Since at least Aug 11, 2026
Janice KaptySVP, Corporate Strategy and Project Leadership · Since at least Apr 15, 2026
Jessica NewcombPrincipal Accounting Officer · Since at least Sep 22, 2026
John B KetchumDirector · Since at least Aug 29, 2023
Julie CarreteroChief Human Resources Officer · Since at least Nov 4, 2026
Julie FogartySVP, General Counsel · Since at least Nov 4, 2026
Kanishka PothulaDirector · Nov 6, 2023 – Nov 6, 2023 · Past
Lesley Ann CalhounEVP, Aligos Therapeutics · Since at least Jun 8, 2026
Malte PetersPresident & Chief Executive Officer, Tango Therapeutics · Since at least Nov 3, 2026
Marc RudoltzChief Medical Officer · Oct 18, 2021 – Nov 1, 2021 · Past
Philippe SerranoChief Regulatory Officer · Since at least Mar 5, 2026
Yen-Ching ChuaChief Development Operations Officer · Since at least Apr 15, 2026

Open People

Log in to ask 6ix AI your own questions about Tango Therapeutics, Inc.